




B. (Z)-1-(diphenylmethyl)-4-(3-phenylprop-2-enyl)piperazine,



C. (4-(diphenylmethyl)-1,1-bis[(E)-3-phenylprop-2-enyl]piperazinium chloride,



D. 1-(diphenylmethyl)-4-[(1R,3E)-4-phenyl-1-(E)-2-phenylethenyl]but-3-enyl]piperazine,



E. 1,4-bis(diphenylmethyl)piperazine.

Comparison: ciprofibrate CRS.

## TESTS

**Appearance of solution.** The solution is clear (2.2.1) and not more intensely coloured than reference solution BY<sub>4</sub> (2.2.2, Method II).

Dissolve 1.0 g in *anhydrous ethanol R* and dilute to 10.0 ml with the same solvent.

**Related substances.** Liquid chromatography (2.2.29).

**Test solution.** Dissolve 0.125 g of the substance to be examined in a mixture of equal volumes of *acetonitrile R* and *water R* and dilute to 50 ml with the same mixture of solvents.

**Reference solution (a).** Dilute 1.0 ml of the test solution to 100.0 ml with a mixture of equal volumes of *acetonitrile R* and *water R*. Dilute 1.0 ml of this solution to 10.0 ml with a mixture of equal volumes of *acetonitrile R* and *water R*.

**Reference solution (b).** Dissolve the contents of a vial of *ciprofibrate for system suitability CRS* in 2.0 ml of a mixture of equal volumes of *acetonitrile R* and *water R*.

**Column:**

- size:  $l = 0.15$  m,  $\emptyset = 4.6$  mm,
- stationary phase: *octylsilyl silica gel for chromatography R* (5  $\mu$ m).

**Mobile phase:**

- mobile phase A: 1.36 g/l solution of *potassium dihydrogen phosphate R* adjusted to pH 2.2 with *phosphoric acid R*,
- mobile phase B: *acetonitrile R*,

Time (min)	Mobile phase A (per cent V/V)	Mobile phase B (per cent V/V)
0 - 30	75 → 30	25 → 70
30 - 40	30	70
40 - 42	30 → 75	70 → 25

**Flow rate:** 1.5 ml/min.

**Detection:** spectrophotometer at 230 nm.

**Injection:** 10  $\mu$ l.

**Identification of impurities:** use the chromatogram supplied with *ciprofibrate for system suitability CRS* to identify the peaks due to impurities A, B, C, D and E.

**Relative retention** with reference to ciprofibrate (retention time = about 18 min): impurity A = about 0.7; impurity B = about 0.8; impurity C = about 0.95; impurity D = about 1.3; impurity E = about 1.5.

**System suitability:** reference solution (b):

- resolution: baseline separation between the peaks due to impurity C and ciprofibrate.


**Limits:**

- correction factor: for the calculation of content, multiply the peak area of impurity A by 2.3,
- impurities A, C, D: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.1 per cent),
- impurity B: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (a) (0.2 per cent),
- impurity E: not more than 8 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.8 per cent),

01/2008:2013

## CIPROFIBRATE

## Ciprofibratum



C<sub>13</sub>H<sub>14</sub>Cl<sub>2</sub>O<sub>3</sub>  
[52214-84-3]

$M_r$  289.2

## DEFINITION

2-[4-[(1R,3E)-2,2-dichlorocyclopropyl]phenoxy]-2-methylpropanoic acid.

**Content:** 99.0 per cent to 101.0 per cent (anhydrous substance).

## CHARACTERS

**Appearance:** white or slightly yellow, crystalline powder.

**Solubility:** practically insoluble in water, freely soluble in anhydrous ethanol, soluble in toluene.

mp: about 115 °C.

## IDENTIFICATION

Infrared absorption spectrophotometry (2.2.24).

- *any other impurity*: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.1 per cent),
- *total of other impurities*: not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.5 per cent),
- *disregard limit*: 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent).

**Chlorides** (2.4.4): maximum 350 ppm.

To 0.190 g add 20 ml of *water R* and treat in an ultrasonic bath for 8 min. Filter. 15 ml of the filtrate complies with the test.

**Water** (2.5.12): maximum 0.5 per cent, determined on 1.000 g.

**Sulphated ash** (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

#### ASSAY

Dissolve 0.250 g in a mixture of 20 ml of *water R* and 40 ml of *anhydrous ethanol R*. Titrate with 0.1 M sodium hydroxide, determining the end-point potentiometrically (2.2.20).


1 ml of 0.1 M sodium hydroxide is equivalent to 28.92 mg of  $C_{17}H_{14}Cl_2O_3$ .

#### STORAGE


In an airtight container, protected from light.

#### IMPURITIES


*Specified impurities: A, B, C, D, E.*



A. 2-(4-ethenylphenoxy)-2-methylpropanoic acid,



B. 4-[(1R)-2,2-dichlorocyclopropyl]phenol,



C. R =  $CH_2OH$ : 2-[4-[(1R)-2,2-dichlorocyclopropyl]phenoxy]-2-methylpropan-1-ol,


D. R =  $CO-OCH_3$ : methyl 2-[4-[(1R)-2,2-dichlorocyclopropyl]phenoxy]-2-methylpropanoate,

E. R =  $CO-OC_2H_5$ : ethyl 2-[4-[(1R)-2,2-dichlorocyclopropyl]phenoxy]-2-methylpropanoate.

01/2008:1089

## CIPROFLOXACIN

### Ciprofloxacinum



$C_{17}H_{18}FN_3O_3$   
[85721-33-1]

$M_r$  331.4

#### DEFINITION

1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid.

*Content*: 99.0 per cent to 101.0 per cent (dried substance).

#### CHARACTERS

*Appearance*: almost white or pale yellow, crystalline powder, slightly hygroscopic.

*Solubility*: practically insoluble in water, very slightly soluble in ethanol and in methylene chloride.

#### IDENTIFICATION

Infrared absorption spectrophotometry (2.2.24).

*Comparison*: ciprofloxacin CRS.

#### TESTS

**Appearance of solution.** The solution is clear (2.2.1) and not more intensely coloured than reference solution GY<sub>5</sub> (2.2.2, Method II).

Dissolve 0.25 g in 0.1 M hydrochloric acid and dilute to 20 ml with the same solvent.

**Impurity A.** Thin-layer chromatography (2.2.27).

*Test solution.* Dissolve 50 mg of the substance to be examined in dilute ammonia R1 and dilute to 5 ml with the same solvent.

*Reference solution.* Dissolve 10 mg of ciprofloxacin impurity A CRS in a mixture of 0.1 ml of dilute ammonia R1 and 90 ml of water R and dilute to 100 ml with water R. Dilute 2 ml of the solution to 10 ml with water R.

*Plate*: TLC silica gel F<sub>254</sub> plate R.

*Application*: 5 µl.

At the bottom of a chromatographic tank, place an evaporating dish containing 50 ml of concentrated ammonia R. Expose the plate to the ammonia vapour for 15 min in the closed tank. Withdraw the plate, transfer to a second chromatographic tank and proceed with development.

*Mobile phase*: acetonitrile R, concentrated ammonia R, methanol R, methylene chloride R (10:20:40:40 V/V/V/V).

*Development*: over 3/4 of the plate.

*Drying*: in air.

*Detection*: examine in ultraviolet light at 254 nm.

#### Limit:

- *impurity A*: any spot corresponding to impurity A is not more intense than the principal spot in the chromatogram obtained with the reference solution (0.2 per cent).